A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers
A single dose of pembrolizumab increased PD-L1 modified proportion score and/or stromal interface immune cells suggesting potential for local tumor immunologic recruitment. Additionally, increases in systemic inflammation, measured by cytokine production and differential IDO1 expression, reflect an interferon response. These hypothesis-generating data need to be confirmed and validated in larger subsets.
Authors
- William S Andrews
- John S. Yi (ORCID: https://orcid.org/0000-0001-7777-2437)
- Stéphanie Gaillard (ORCID: https://orcid.org/0000-0002-2174-3693)
- Brittany Anne Davidson (ORCID: https://orcid.org/0000-0001-9698-0442)
- Andrew Berchuck (ORCID: https://orcid.org/0000-0002-1940-1467)
- Andrew B. Nixon (ORCID: https://orcid.org/0000-0003-3971-2964)
- Jose Ramon Conejo-Garcia (ORCID: https://orcid.org/0000-0001-6431-4074)
- Mark D. Starr (ORCID: https://orcid.org/0009-0003-9664-6235)
- Jadee Neff (ORCID: https://orcid.org/0000-0002-4924-4247)
- Rebecca A. Previs (ORCID: https://orcid.org/0000-0001-8087-9120)
- Laura Jean Havrilesky (ORCID: https://orcid.org/0000-0002-4259-5992)
- Gloria Broadwater
- Angeles Alvarez Secord
Institutions
- Gynecologic Oncology Group (US)
- Johns Hopkins University (US)
- Duke Medical Center (US)
- Laboratoire d’immunologie intégrative du cancer (FR)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1016/j.gore.2025.101770
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00